NIOX Group (LSE:NIOX) has built a Business around a single, clever idea: measuring inflammation in the airways to help diagnose and manage asthma. Its devices are used by clinicians worldwide, but the real prize is not the hardware. It is the steady stream of consumable test kits that each device consumes, turning asthma testing into recurring revenue.
A specialist diagnostics business
NIOX makes devices that measure fractional exhaled nitric oxide, known as FeNO, a marker of airway inflammation that helps clinicians diagnose asthma and guide treatment. The company sells its devices to hospitals, clinics and researchers, and each test requires a single-use kit. This razor-and-blade model means that once a device is installed, it generates ongoing Demand for consumables, creating a Recurring Revenue stream that grows as the installed base expands and testing volumes rise.
The 2025 results
For the year to 31 December 2025, NIOX reported revenue of about £48.7 million, up 17%, comprising clinical revenue of roughly £38.6 million, up 7%, and research revenue of about £10.1 million, up 77% as pharmaceutical-sponsored studies reached unusually high levels. Adjusted EBITDA rose about 21% to around £16.7 million at a 34% margin, and the company ended the year with cash of about £19.9 million, up markedly, having paid a Dividend during the year. It also launched its next-generation NIOX PRO device.
The recurring-revenue engine
The heart of the model is consumables. Test-kit revenues represented about 92% of clinical sales, showing how dependent – and dependable – that recurring stream is. Every device placed with a clinician becomes a long-term source of kit sales, so growing the installed base is the key to compounding revenue. The launch of the NIOX PRO device is designed to drive new placements, which in turn should lift future consumable demand, reinforcing the recurring engine that underpins the group’s attractive margins.
Structural demand for FeNO
NIOX benefits from growing clinical acceptance of FeNO testing. Health systems increasingly recognise that better asthma diagnosis and monitoring can improve outcomes and reduce costs, and clinical guidelines in several countries support FeNO use. As adoption spreads, more clinicians install devices and run more tests, expanding NIOX’s addressable market. This structural tailwind, combined with the recurring consumables model, is what gives the company a credible path to sustained, profitable growth rather than one-off device sales.
The risks to weigh
There are risks to weigh. The unusually strong research revenue in 2025 may normalise, as management itself cautioned, so growth could moderate. NIOX relies on clinical adoption and favourable guidelines, which vary by country and could change. Competition and alternative diagnostic approaches exist, and reimbursement decisions affect demand. As a specialist device maker, it must keep innovating, and currency movements affect a globally selling company. Concentration on a single testing technology also limits diversification.
So how does testing become recurring revenue?
NIOX turns asthma testing into recurring revenue through its razor-and-blade model: placing devices that generate ongoing demand for single-use test kits, which already make up the vast majority of clinical sales. Growing the installed base, helped by the new NIOX PRO device and rising clinical acceptance of FeNO, compounds that consumable income. Research revenue may ebb and flow, and adoption and competition are risks. But the recurring kit sales give NIOX a durable, high-margin core on which to build. The 2025 surge in research revenue may not repeat, so the steadier clinical consumables stream is what investors should watch most closely. If NIOX keeps placing devices and growing test volumes, the recurring model should compound quietly over time, which is precisely the kind of dependable growth that rewards patience over many years.






Please wait processing your request...